Priorities in research and development of vaccines against Plasmodium vivax malaria.
The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D). This document summarizes a MALVAC scientific consultation of leading vaccine scientists on priorities in Plasmodium vivax vaccine R&D. The meeting discussed recent advances and key challenges in addressing identified gaps in knowledge. Major areas of discussion included disease burden estimates, clinical disease spectrum definitions, potential target product profiles and immunological and clinical research needed to better inform antigen selection and vaccine design. The need for further development of the human challenge model for P. vivax vaccines and specific considerations for conduct of field trials with P. vivax vaccines was outlined. This report summarizes the discussion and conclusions of the consultation, with recommendations for priority targeted research.
Brown
Graham V
GV
Nossal Institute for Global Health, Centre for Clinical Research Excellence in Infectious Diseases, University of Melbourne, Carlton, Victoria 3010, Australia.
Moorthy
Vasee S
VS
Reed
Zarifah
Z
Mendis
Kamini
K
Arévalo-Herrera
Myriam
M
Alonso
Pedro
P
D026683:Advisory Committees; D000953:Antigens, Protozoan / Q000276:immunology; D002986:Clinical Trials as Topic; D017281:Cost of Illness; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology / Q000494:pharmacology* / Q000592:standards; D016780:Malaria, Vivax / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D012008:Recurrence; D012106:Research; D014944:World Health Organization
D000953:Antigens, Protozoan; D017780:Malaria Vaccines